Developer docs
API playgroundTry for free, no card

Search company profiles

Optiscan

Full company profile

uuid0037v3x

Namestring
Optiscan
Legal namestring
Optiscan Imaging Ltd
Websiteurl
optiscan.com
Company typeenum
Public
Founded yearint
1994
Descriptiontext

Optiscan Imaging Ltd is an Australian medical technology company founded in 1994 that develops and manufactures proprietary confocal laser endomicroscopy systems enabling real-time, non-destructive, in vivo digital imaging at single-cell resolution (0.55µm). The company, headquartered in Melbourne with a manufacturing facility producing approximately 50 systems per year and a US subsidiary in Rochester, Minnesota, sells a portfolio of five products (InVue for precision surgery, InForm for digital pathology, InVivage for dental/oral applications, ViewnVivo for preclinical life sciences research, and InSpecta for veterinary medicine) to hospitals, pathology laboratories, veterinary practices, dental clinics, and academic research institutions across Australia, the United States, Europe, and Asia Pacific. Revenue is generated through capital equipment sales (quote-based multi-year enterprise contracts), recurring software and AI solutions including cloud-based telepathology streaming co-developed with Prolucid Technologies, and ongoing service and support contracts. The company maintains ISO 13485:2016 certification and is pursuing FDA regulatory clearance for US market entry while leveraging co-development partnerships with Mayo Clinic (robotic surgery imaging), Carl Zeiss Meditec (CONVIVO for neurosurgery), and Monash University (next-generation GI endomicroscope).

Short descriptiontext

Optiscan Imaging Ltd is an Australian medtech company that develops and manufactures proprietary confocal laser endomicroscopy systems for real-time, slide-free, biopsy-free single-cell imaging, serving hospitals, pathology labs, veterinary practices and research institutions across multiple global markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMulgrave, Australia
HQ citystring
Mulgrave
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
confocal endomicroscopy, digital pathology imaging, precision surgery imaging, medical imaging devices, in vivo cellular imaging
Industry4 codes
1Endoscopy Systems & Accessories (Scopes, Cameras, Light Sources, Insufflation)
CodeHLAHADABPrimaryYes
2Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence)
CodeHLAHADAHPrimaryNo
3Imaging Equipment & Accessories (X-ray, Ultrasound, Endoscopy)
CodeHLAMAFACPrimaryNo
4Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity)
CodeHLACABAMPrimaryNo
NAICS code3 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Analytical Laboratory Instrument Manufacturing334516
  • Surgical and Medical Instrument Manufacturing339112
SIC code3 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Laboratory Analytical Instruments3826
  • Optical Instruments & Lenses3827
Product category
Medical Imaging Devices
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Medical Imaging Device Sales
TypeHardware Sales
Description

Sale of proprietary confocal endomicroscopic imaging systems including InVue, InForm, InVivage, InSpecta, and ViewnVivo devices for medical, veterinary, and life sciences applications

optiscan.com
2Software and AI Solutions
TypeSubscription Recurring
Description

Cloud-based telepathology streaming services and AI-powered image analysis software-as-a-medical-device co-developed with Prolucid Technologies for digital pathology workflows

optiscan.com
3Service and Support
TypeProfessional Services
Description

Applications support, customer support, and ongoing maintenance services for imaging systems

optiscan.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure
Pricing details1 tier
1Enterprise/B2B medical device pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based / Not publicly disclosed

optiscan.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Optiscan develops, manufactures, and sells proprietary confocal endomicroscopy imaging systems for medical, veterinary, dental, and life sciences applications. Its product portfolio includes InVue (precision surgery), InForm (digital pathology), InVivage (intra-oral), ViewnVivo (preclinical research), and InSpecta (veterinary), all built on a miniaturized fiber optic platform delivering real-time, biopsy-free, slide-free, in-vivo imaging at single-cell resolution. The company complements hardware sales with AI-powered image analysis software, cloud-based telepathology streaming, and applications/service support.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Real-time imaging capability eliminating hours to days of traditional pathology turnaround
+2 more records
Product overview1 text field

Optiscan offers a portfolio of five distinct real-time confocal endomicroscopic imaging products serving different market segments. The portfolio includes: InVue (precision surgery), InForm (digital pathology), InVivage (dental/oral), ViewnVivo (preclinical research), and InSpecta (veterinary medicine). All products share the core patented technology platform enabling real-time, slide-free, biopsy-free, in-vivo cellular imaging at 0.55μm resolution. The platform integrates hardware devices with software capabilities including AI-powered image analysis, telepathology streaming, and PACS connectivity.

Product and service5 records
1Optiscan InVue
CategoryPrecision Surgery Imaging
Description

A microscopic medical imaging device for precision surgery using confocal laser endomicroscopy with a fiber-optic probe for real-time, in-vivo visualization of internal tissue microstructure. Designed for breast, head, neck, and other surgeries, placing digital pathology directly in surgeons' hands for intraoperative decision-making.

2Optiscan InForm
CategoryDigital Pathology Imaging
Description

A next-generation digital pathology imaging device providing real-time, slide-free cellular imaging at point of tissue collection, eliminating the need for traditional slide preparation and tissue processing. DICOM-compatible and PACS-enabled for laboratory and surgical environments.

3Optiscan InVivage
CategoryDental and Oral Health Imaging
Description

An intra-oral digital endomicroscope providing virtual histology of the oral cavity for identification of tissue disease, monitoring of mucosal lesions, and mapping of surgical margins. Features a miniaturized 4mm diameter handheld probe, ORIS operating system for dental workflow, and DICOM-compatible/PACS-enabled image transmission.

4Optiscan ViewnVivo
CategoryPreclinical Research Imaging
Description

A life-sciences endomicroscope for research applications providing high-resolution, portable, flexible intravital fluorescence confocal imaging for preclinical and translational research. Designed for in-vivo cellular imaging in animal models and tissue culture with Z-stack capability up to 400 microns depth.

5Optiscan InSpecta
CategoryVeterinary Imaging
Description

A veterinary-first digital microscopic imaging device delivering real-time, cellular-level imaging at point of care without slides, tissue processing, or lab delays. Compact, portable system with adjustable imaging depth up to 150µm, designed for species-agnostic use in veterinary practices.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-10
Description

Collaboration Agreement with Australia's leading private pathology provider to support deployment, evaluation and testing of InForm digital pathology platform.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-23
Description

US pharmaceutical partnership to support FDA submissions, integrating Optiscan's imaging technology with drug development and clinical trial processes.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-19
Description

Collaboration with leading US veterinary teaching and research institution to advance clinical evaluation of InSpecta and explore new veterinary applications for real-time imaging technology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-05
Description

Agreement to progress project for scope-agnostic GI flexible endomicroscope and next-generation AI technology. Original technology was created at Monash University.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-14
Description

Know-How Agreement for development of a digital endomicroscopic imaging system designed for robotic-assisted surgery. Collaboration combines Optiscan's engineering expertise with Mayo Clinic's robotic surgery and patient care capabilities. Initial focus on breast cancer surgery with all key engineering milestones completed. Agreement extended until 12 August 2026.

Strategic tierSecondaryTypeChannel Partner/ Reseller/ DistributorAnnounced on2020-12-16
Description

Exclusive pre-clinical distributor for Taiwan, distributing ViewnVivo products for life sciences research applications.

Strategic tierCoreTypeTechnology or Integration
Description

Canadian-based software engineering firm engaged to co-develop Optiscan's cloud-based telepathology streaming service and AI software-as-a-medical-device for the endomicroscopy product suite.

Strategic tierSecondaryTypeTechnology or Integration
Description

Working with Capgemini's Design Industry team to co-develop next generation endomicroscopic imaging platform and device portfolio.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

CONVIVO collaboration resulting in live microscopic imaging technology for neurosurgery. Carl Zeiss Meditec commercializes Optiscan's confocal imaging technology customized for specific medical applications.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical studies with Australia's leading public teaching hospital to evaluate InVue and InForm devices in breast cancer surgery.

Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

Clinical trial as part of broader clinical program evaluating imaging technologies in head and neck cancer surgery.

Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

Collaboration with leading US companion animal practice for clinical evaluation and early commercial introduction of InSpecta veterinary device.

13University Medical Center Mainz
Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

Pre-clinical gastrointestinal study supporting evaluation of endomicroscopy technology in GI applications.

optiscan.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

Specialist in optical/photonic components and digital slide scanners. Adjacent competitor/supplier in optical imaging and pathology workflows relevant to confocal endomicroscopy.

TypeBroad incumbent
Description

Danaher-owned microscopy and pathology imaging company. Competes with Optiscan's ViewnVivo life-science endomicroscope and broader pathology imaging solutions.

TypeBroad incumbent
Description

Global leader in endoscopy systems. Competes with Optiscan's endoscopic imaging across GI and surgical endoscopy, and offers integrated digital/AI workflows at much larger scale.

TypeBroad incumbent
Description

Broad surgical-imaging and equipment incumbent with extensive neurosurgery, ENT, and orthopedic visualization portfolios. Competes with Optiscan's intraoperative and precision-surgery applications.

TypeDirect peer
Description

Strategic partner that already commercializes Optiscan's CONVIVO technology in neurosurgery, and a broad incumbent in intraoperative/surgical microscopy and ophthalmic devices. Overlapping product portfolio in surgical imaging and digital pathology.

TypeBroad incumbent
Description

Large incumbent in digital pathology (IntelliSite) and clinical imaging. Competes with Optiscan's InForm digital pathology platform at the hospital-IT integration level.

TypeDirect peer
Description

Paris-based pioneer of confocal laser endomicroscopy (Cellvizio). Most direct comparable to Optiscan's core technology platform across GI, pulmonary, and surgical applications; same customer base of specialists seeking in vivo cellular imaging.

TypeDirect peer
Description

Hungarian vendor of digital pathology scanners and workflow software. Direct competitor in slide-free/slide-based pathology workflows targeted by Optiscan InForm.

TypeBroad incumbent
Description

Life-science and microscopy instrumentation vendor with preclinical imaging products overlapping ViewnVivo's translational research use case.

10Eleméd Technologies (POCUS / point-of-care ultrasound for vet)
TypeEmerging player
Description

Point-of-care imaging providers in veterinary settings (e.g., GE HealthCare veterinary ultrasound, Clarius, etc.). Compete with InSpecta for veterinary point-of-care diagnostic imaging budgets, though using a different modality.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Optiscan

Medical Imaging Devicesoptiscan.com

Optiscan Imaging Ltd is an Australian medtech company that develops and manufactures proprietary confocal laser endomicroscopy systems for real-time, slide-free, biopsy-free single-cell imaging, serving hospitals, pathology labs, veterinary practices and research institutions across multiple global markets.

What Optiscan does

Optiscan Imaging Ltd is an Australian medical technology company founded in 1994 that develops and manufactures proprietary confocal laser endomicroscopy systems enabling real-time, non-destructive, in vivo digital imaging at single-cell resolution (0.55µm). The company, headquartered in Melbourne with a manufacturing facility producing approximately 50 systems per year and a US subsidiary in Rochester, Minnesota, sells a portfolio of five products (InVue for precision surgery, InForm for digital pathology, InVivage for dental/oral applications, ViewnVivo for preclinical life sciences research, and InSpecta for veterinary medicine) to hospitals, pathology laboratories, veterinary practices, dental clinics, and academic research institutions across Australia, the United States, Europe, and Asia Pacific. Revenue is generated through capital equipment sales (quote-based multi-year enterprise contracts), recurring software and AI solutions including cloud-based telepathology streaming co-developed with Prolucid Technologies, and ongoing service and support contracts. The company maintains ISO 13485:2016 certification and is pursuing FDA regulatory clearance for US market entry while leveraging co-development partnerships with Mayo Clinic (robotic surgery imaging), Carl Zeiss Meditec (CONVIVO for neurosurgery), and Monash University (next-generation GI endomicroscope).

Optiscan firmographics

Firmographics
Name
Optiscan
Legal name
Optiscan Imaging Ltd
Website
https://optiscan.com
Company type
Public
Founded year
1994
Operating status
Operating
Headcount range
11–50 employees
Short description
Optiscan Imaging Ltd is an Australian medtech company that develops and manufactures proprietary confocal laser endomicroscopy systems for real-time, slide-free, biopsy-free single-cell imaging, serving hospitals, pathology labs, veterinary practices and research institutions across multiple global markets.
Ownership category
akta.pro rank

Optiscan industry classification

Industry
Product category
Medical Imaging Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Analytical Laboratory Instrument Manufacturing (334516), Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841), Laboratory Analytical Instruments (3826), Optical Instruments & Lenses (3827)
akta.pro primary industry
Endoscopy Systems & Accessories (Scopes, Cameras, Light Sources, Insufflation) (HLAHADAB)
akta.pro secondary industries
Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence) (HLAHADAH), Imaging Equipment & Accessories (X-ray, Ultrasound, Endoscopy) (HLAMAFAC), Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity) (HLACABAM)

Keywords

  • Confocal endomicroscopy
  • Digital pathology imaging
  • Precision surgery imaging
  • Medical imaging devices
  • In vivo cellular imaging

Where Optiscan is headquartered

Location

Headquarters

HQ city
Mulgrave
HQ country
Australia
HQ region
Oceania

Offices5 records

Markets served

Optiscan business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Imaging Device Sales: Sale of proprietary confocal endomicroscopic imaging systems including InVue, InForm, InVivage, InSpecta, and ViewnVivo devices for medical, veterinary, and life sciences applications
  2. Software and AI Solutions: Cloud-based telepathology streaming services and AI-powered image analysis software-as-a-medical-device co-developed with Prolucid Technologies for digital pathology workflows
  3. Service and Support: Applications support, customer support, and ongoing maintenance services for imaging systems

Pricing tiers

ModelBillingPrice
OtherMulti-year contractEnterprise/B2B medical device pricing

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Optiscan product offering

Product offering

Core offering

Optiscan develops, manufactures, and sells proprietary confocal endomicroscopy imaging systems for medical, veterinary, dental, and life sciences applications. Its product portfolio includes InVue (precision surgery), InForm (digital pathology), InVivage (intra-oral), ViewnVivo (preclinical research), and InSpecta (veterinary), all built on a miniaturized fiber optic platform delivering real-time, biopsy-free, slide-free, in-vivo imaging at single-cell resolution. The company complements hardware sales with AI-powered image analysis software, cloud-based telepathology streaming, and applications/service support.

Product overview

Optiscan offers a portfolio of five distinct real-time confocal endomicroscopic imaging products serving different market segments. The portfolio includes: InVue (precision surgery), InForm (digital pathology), InVivage (dental/oral), ViewnVivo (preclinical research), and InSpecta (veterinary medicine). All products share the core patented technology platform enabling real-time, slide-free, biopsy-free, in-vivo cellular imaging at 0.55μm resolution. The platform integrates hardware devices with software capabilities including AI-powered image analysis, telepathology streaming, and PACS connectivity.

Differentiator

Problem solved

Functional benefit

Products and services

  • Optiscan InVue A microscopic medical imaging device for precision surgery using confocal laser endomicroscopy with a fiber-optic probe for real-time, in-vivo visualization of internal tissue microstructure. Designed for breast, head, neck, and other surgeries, placing digital pathology directly in surgeons' hands for intraoperative decision-making.
  • Optiscan InForm A next-generation digital pathology imaging device providing real-time, slide-free cellular imaging at point of tissue collection, eliminating the need for traditional slide preparation and tissue processing. DICOM-compatible and PACS-enabled for laboratory and surgical environments.
  • Optiscan InVivage An intra-oral digital endomicroscope providing virtual histology of the oral cavity for identification of tissue disease, monitoring of mucosal lesions, and mapping of surgical margins. Features a miniaturized 4mm diameter handheld probe, ORIS operating system for dental workflow, and DICOM-compatible/PACS-enabled image transmission.
  • Optiscan ViewnVivo A life-sciences endomicroscope for research applications providing high-resolution, portable, flexible intravital fluorescence confocal imaging for preclinical and translational research. Designed for in-vivo cellular imaging in animal models and tissue culture with Z-stack capability up to 400 microns depth.
  • Optiscan InSpecta A veterinary-first digital microscopic imaging device delivering real-time, cellular-level imaging at point of care without slides, tissue processing, or lab delays. Compact, portable system with adjustable imaging depth up to 150µm, designed for species-agnostic use in veterinary practices.

Quantifiable outcome

  • Real-time imaging capability eliminating hours to days of traditional pathology turnaround
  • +2 more outcomes

Companies that use Optiscan

Customer profile

Named customers7 records

Segments5 records

Ideal customer profiles4 records

Optiscan technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability3 records

Feature4 records

Optiscan partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core and secondary.

  • Australian Clinical LabscoreStrategic or Co-development Partner · 10 November 2025Collaboration Agreement with Australia's leading private pathology provider to support deployment, evaluation and testing of InForm digital pathology platform.
  • Long Grove PharmaceuticalscoreStrategic or Co-development Partner · 23 June 2025US pharmaceutical partnership to support FDA submissions, integrating Optiscan's imaging technology with drug development and clinical trial processes.
  • University of Minnesota College of Veterinary MedicinecoreStrategic or Co-development Partner · 19 November 2024Collaboration with leading US veterinary teaching and research institution to advance clinical evaluation of InSpecta and explore new veterinary applications for real-time imaging technology.
  • Monash UniversitycoreStrategic or Co-development Partner · 5 November 2024Agreement to progress project for scope-agnostic GI flexible endomicroscope and next-generation AI technology. Original technology was created at Monash University.
  • Mayo CliniccoreStrategic or Co-development Partner · 14 May 2024Know-How Agreement for development of a digital endomicroscopic imaging system designed for robotic-assisted surgery. Collaboration combines Optiscan's engineering expertise with Mayo Clinic's robotic surgery and patient care capabilities. Initial focus on breast cancer surgery with all key engineering milestones completed. Agreement extended until 12 August 2026.
  • J&H Technology Co LtdsecondaryChannel Partner/ Reseller/ Distributor · 16 December 2020Exclusive pre-clinical distributor for Taiwan, distributing ViewnVivo products for life sciences research applications.
  • Prolucid TechnologiescoreTechnology or IntegrationCanadian-based software engineering firm engaged to co-develop Optiscan's cloud-based telepathology streaming service and AI software-as-a-medical-device for the endomicroscopy product suite.
  • Capgemini (formerly D+I)secondaryTechnology or IntegrationWorking with Capgemini's Design Industry team to co-develop next generation endomicroscopic imaging platform and device portfolio.
  • Carl Zeiss MediteccoreOEM/ Whitelabel/ Licensing PartnerCONVIVO collaboration resulting in live microscopic imaging technology for neurosurgery. Carl Zeiss Meditec commercializes Optiscan's confocal imaging technology customized for specific medical applications.
  • Royal Melbourne HospitalcoreStrategic or Co-development PartnerClinical studies with Australia's leading public teaching hospital to evaluate InVue and InForm devices in breast cancer surgery.
  • St John of God Murdoch HospitalsecondaryStrategic or Co-development PartnerClinical trial as part of broader clinical program evaluating imaging technologies in head and neck cancer surgery.
  • Arizona Animal HospitalsecondaryStrategic or Co-development PartnerCollaboration with leading US companion animal practice for clinical evaluation and early commercial introduction of InSpecta veterinary device.
  • University Medical Center MainzsecondaryStrategic or Co-development PartnerPre-clinical gastrointestinal study supporting evaluation of endomicroscopy technology in GI applications.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Optiscan competitors and assessment

Company assessment

Others

  • Hamamatsu Photonics: Specialist in optical/photonic components and digital slide scanners. Adjacent competitor/supplier in optical imaging and pathology workflows relevant to confocal endomicroscopy.

Broad incumbents

  • Leica Microsystems (Danaher): Danaher-owned microscopy and pathology imaging company. Competes with Optiscan's ViewnVivo life-science endomicroscope and broader pathology imaging solutions.
  • Olympus Corporation: Global leader in endoscopy systems. Competes with Optiscan's endoscopic imaging across GI and surgical endoscopy, and offers integrated digital/AI workflows at much larger scale.
  • Stryker: Broad surgical-imaging and equipment incumbent with extensive neurosurgery, ENT, and orthopedic visualization portfolios. Competes with Optiscan's intraoperative and precision-surgery applications.
  • Philips (Digital Pathology): Large incumbent in digital pathology (IntelliSite) and clinical imaging. Competes with Optiscan's InForm digital pathology platform at the hospital-IT integration level.
  • Bruker Corporation: Life-science and microscopy instrumentation vendor with preclinical imaging products overlapping ViewnVivo's translational research use case.

Direct peers

  • Carl Zeiss Meditec: Strategic partner that already commercializes Optiscan's CONVIVO technology in neurosurgery, and a broad incumbent in intraoperative/surgical microscopy and ophthalmic devices. Overlapping product portfolio in surgical imaging and digital pathology.
  • Mauna Kea Technologies (Cellvizio): Paris-based pioneer of confocal laser endomicroscopy (Cellvizio). Most direct comparable to Optiscan's core technology platform across GI, pulmonary, and surgical applications; same customer base of specialists seeking in vivo cellular imaging.
  • 3DHISTECH (3DHistech Ltd.): Hungarian vendor of digital pathology scanners and workflow software. Direct competitor in slide-free/slide-based pathology workflows targeted by Optiscan InForm.

Emerging players

  • Eleméd Technologies (POCUS / point-of-care ultrasound for vet): Point-of-care imaging providers in veterinary settings (e.g., GE HealthCare veterinary ultrasound, Clarius, etc.). Compete with InSpecta for veterinary point-of-care diagnostic imaging budgets, though using a different modality.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Optiscan social profiles

Digital presence

Optiscan compliance and trust

Trust signal

Compliance4 records

Optiscan financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Optiscan leadership team

Management profile

Number of profiles

Profiles17 records

Optiscan subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Optiscan funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Optiscan M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Optiscan

What does Optiscan do?

Optiscan develops, manufactures, and sells proprietary confocal endomicroscopy imaging systems for medical, veterinary, dental, and life sciences applications. Its product portfolio includes InVue (precision surgery), InForm (digital pathology), InVivage (intra-oral), ViewnVivo (preclinical research), and InSpecta (veterinary), all built on a miniaturized fiber optic platform delivering real-time, biopsy-free, slide-free, in-vivo imaging at single-cell resolution. The company complements hardware sales with AI-powered image analysis software, cloud-based telepathology streaming, and applications/service support.

Is Optiscan a public or private company?

Optiscan is a public company. It is classified as public and is currently operating.

When was Optiscan founded?

Optiscan was founded in 1994. It employs 11 to 50 people.

Where is Optiscan based?

Optiscan is headquartered in Mulgrave, Australia, in the Oceania region.

How does Optiscan make money?

Three revenue lines are on record. Medical Imaging Device Sales are the primary driver. The others are software and AI Solutions and service and Support.

Who are Optiscan's main competitors?

Hamamatsu Photonics is listed as an others. Broad incumbents are Leica Microsystems (Danaher), Olympus Corporation, Stryker, Philips (Digital Pathology) and Bruker Corporation. Direct peers are Carl Zeiss Meditec, Mauna Kea Technologies (Cellvizio) and 3DHISTECH (3DHistech Ltd.). Eleméd Technologies (POCUS / point-of-care ultrasound for vet) is listed as an emerging player.

Does Optiscan have an API?

No public API is recorded for Optiscan.

What industry is Optiscan in?

Optiscan's product category is Medical Imaging Devices. Its primary akta.pro industry code is HLAHADAB, Endoscopy Systems & Accessories (Scopes, Cameras, Light Sources, Insufflation), with a secondary code of HLAHADAH, Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
KalkineOptiscan Imaging (ASX:OIL): Share Price Decline Brings Focus to Advanced Imaging SolutionsOptiscan Imaging Limited shares declined 2.70% to close at $0.18 on 13 August 2026, amidst a broader downturn in Australian equity markets. The company continues to develop advanced medical imaging technologies for healthcare and research applications within the specialized medical technology sector.MarketScreenerOptiscan Imaging to Commence US Clinical Study for InVue, InForm Devices in Breast Conserving Surgery, Shares Up 7%Optiscan Imaging Limited announced it will commence a US clinical study for its InVue and InForm devices used in breast conserving surgery. The company's shares rose 7% following the announcement. The devices are part of Optiscan's suite of digital pathology and precision surgery solutions that enable real-time, non-destructive in-vivo digital imaging at the single-cell level.AInvestOptiScan Imaging Ltd: OptiScan signs new research agreement for breast studyOptiScan Imaging Ltd has signed a new research agreement focused on a breast study, according to a brief announcement published on July 21, 2026. The article provides minimal detail on the study's scope, financial terms, or strategic implications. No information is disclosed regarding the research partner, study timeline, or expected outcomes.The AustralianOptiscan launches InSpecta in USOptiscan Imaging has launched InSpecta, its first clinical veterinary microscopic imaging device, in the US market following submission of a regulatory dossier to the FDA Centre for Veterinary Medicine. The launch marks Optiscan's transition from a technology developer to a commercial enterprise, establishing an in-house imaging capability for veterinary practices and providing a validated regulatory pathway for future product submissions. The company aims to target the US veterinary services market, valued at approximately US$15.87 billion in 2024, with plans to showcase the device at the AVMA Convention 2026 in California.ShareCafeOptiscan Marks Two-Year Milestone in Mayo Clinic Collaboration for Robotic Surgery ImagingOptiscan Imaging Ltd announced the two-year milestone of its Know-How Agreement with Mayo Clinic, marking significant progress in developing a digital endomicroscopic imaging system for robotic surgery, with all key engineering milestones and development objectives successfully completed. The collaboration has included concept development, feasibility assessments, prototype development, and comprehensive integration testing, with surgeons from Mayo Clinic and Optiscan staff assessing the technology's fit within robotic-assisted breast surgery workflows. The Agreement has been extended until 12 August 2026 to facilitate strategic, clinical, and commercial planning, reinforcing Optiscan's standing in robotic surgery and supporting its US expansion strategy.KalkineOptiscan Imaging (ASX:OIL) Gains After Reporting Progress in Robotic Surgery InitiativeOptiscan Imaging announced that its Know-How Agreement with Mayo Clinic has reached its two-year milestone, with all major engineering objectives completed for the development of a digital endomicroscopic imaging system designed for robotic-assisted surgery. The collaboration has been extended until 12 August 2026 to support strategic, clinical, and commercial planning activities, as the project progresses toward preclinical testing. The market responded favourably, with Optiscan shares rising 6.38% to AUD 0.12 on 1 June 2026, reflecting investor confidence in the continued advancement of the partnership.TradingViewOptiscan Submits FDA Dossier for Inspecta Imaging Device Targeting Lucrative US Veterinary MarketOptiscan has submitted a regulatory dossier to the US Food and Drug Administration for its InSpecta digital microscopic imaging device designed for the veterinary medicine market, marking a key milestone in its US market entry strategy. The submission, which includes device design specifications, workflow integration data, and validation testing results, initiates formal regulatory review and establishes a framework for future product submissions across Optiscan's portfolio. The US veterinary market was valued at approximately US$11.92 billion in 2022 with an 8.7% compound annual growth rate projected through 2030.TipranksOptiscan underscores role as leader in real-time 3D medical imagingOptiscan Imaging Limited announced its leadership in high-resolution medical imaging technologies that enable real-time, 3D in-vivo imaging at the single-cell level. The company's focus is on integrating digital imaging solutions into surgical and diagnostic workflows to improve clinical decision-making. It targets clinical and pre-clinical markets, supporting ongoing engagement with research institutions and medical innovation.Manufacturers' MonthlyOptiscan – Manufacturing an alternative to invasive diagnosisOptiscan is an Australian medical technology company founded in 1994 that manufactures a pen-sized digital microscope enabling real-time, in-vivo cellular imaging at 0.55µm resolution, offering a non-invasive alternative to traditional biopsies and slide-based pathology. The company produces four product lines—InVue for surgery, InForm for pathology, InVivage for dental, and ViewnVivo for preclinical research—with all manufacturing based in Melbourne, Victoria at approximately 50 systems per year capacity. CEO Dr. Camile Farah outlined future plans including expansion into veterinary medicine, endoscopic applications, AI-driven image analysis, and telepathology streaming software planned for later this year.OptiscanOptiscan extends robotic arm with US medical imaging dealOptiscan has entered a collaboration with Mayo Clinic to develop digital laser imaging technology for robotic surgery, initially targeting breast cancer patients. The two companies will combine their expertise to build the imaging system over two years, with Mayo committing a financial interest in Optiscan's technology.